By Julie Severson
Some of the most cutting-edge clinical studies are those that employ recombinant DNA (rDNA) therapies and utilize biotechnology and bioengineering methods. Because such studies often require Institutional Biosafety Committee (IBC)—in addition to Institutional Review Board (IRB)—approval, they necessitate increased coordination. Yet mastery of dual IRB and IBC review has proven elusive, whether this review is administered at the research site or outsourced to another company. Researchers, funders, and administrators must absorb the additional work and expense, and they are left wanting a new paradigm.
Quorum Review IRB delivers coordinated IRB and IBC review.
We recently launched a line of IBC services that integrates human subject protection and biosafety review. With the goal of minimizing the burden and cost for clients, we researched and implemented processes that heighten coordination and maximize efficiency. Needless to say, we are eager to share the results.